In February 2021, we organised our Annual Networking Event, attended by industry, our key partners, and members organisations, to discuss our plans and future collaboration opportunities. We looked back at EMSP’s main achievements in 2020 and outlined our common priorities for 2021 and beyond.
Work with the European Medicines Agency / EUnetHTA
EMSP is a member of the Patient and Consumer Working Party and the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). By being an active member within EMA, EMSP is looking to extend an intensive cooperation between MS patients and the EMA to involve people with MS in all possible procedures within EMA. Patients’ contribution is particularly important for pharmacovigilance, e.g., adverse drug reaction reporting, as well as encouraging national authorities to implement all rules of the Pharmacovigilance Directive. Another major issue in which EMSP is involved is risk/benefit assessment and the communication towards patients on this issue.
EMSP is a collaborating partner of EUnetHTA, a EU Commission-established initiative to create an effective and sustainable network for Health Technology Assessment (HTA) across Europe. EMSP provides support in terms of effectiveness of HTA models, and strives for better patient involvement in processes impacting the access to treatment for people affected by MS.
EMSP kept its contribution in broader alliances to ensure the voice of the people affected by MS is represented, with the aim of increasing visibility of neurological diseases on the political agenda through the inclusion of MS as an example in broader campaigns and initiatives.
EMSP collaborates closely with the European Brain Council (EBC) and the Multiple Sclerosis International Federation (MSIF)
EMSP is a member of the European Patients’ Forum (EPF), the European Disability Forum (EDF) and the European Federation of Neurological Associations (EFNA)
EMSP regularly collaborates with healthcare professionals and the scientific community, such as Rehabilitation in MS (RiMS), the European Committee for Treatment and Research in MS (ECTRIMS) or the European Charcot Foundation
EMSP is also a member of the EFPIA Patient Think Tank. EMSP has also a Memorandum of Understanding with Caritas Norway.